As millions await approved therapies, myTomorrows strengthens its global patient-access mission with €25 million

myTomorrows, a Dutch HealthTech firm that links individuals with feasible pre-approval therapies, today introduced the close of a EUR25 million funding in order to increase the worldwide development of its AI-driven system and boost accessibility to arising treatments for individuals worldwide.

Avego’s development equity financial investment will certainly sustain the worldwide development of myTomorrows’ incorporated pharma services to make arising therapies much more fair and easily accessible for individuals internationally.

“ This financial investment notes a crucial action in our trip to provide every client, despite where they live, a reasonable chance at tomorrow’s treatments,” stated Michel van Harten, chief executive officer of myTomorrows. “ Avego’s considerable know-how in life scientific researches, specifically BioPharma, will certainly contribute as we scale our system and expand our influence throughout the worldwide wellness landscape“

This growth-equity financial investment in myTomorrows lines up with numerous remarkable 2025 European HealthTech financing rounds.

In Belgium, Sequana Medical protected EUR24 million to sustain the United States launch of its “alfapump” gadget for persistent fluid-retention administration. In France, ArcaScience increased EUR6 million to boost AI-driven benefit-risk knowledge for medication advancement. On the other hand, Finland’s CurifyLabs acquired EUR6.7 million to modernise the manufacturing of customised medications.

While these firms run in nearby sectors of the wider HealthTech and BioPharma landscape, myTomorrows stands apart for its concentrate on client accessibility to pre-approval treatments with an AI-enabled system that links medical professionals, test websites, and biopharma companions.

Its round stands for among the much more considerable Dutch HealthTech fundings reported in 2025, underscoring ongoing capitalist self-confidence in innovation services that connect early-stage medication advancement and client gain access to.

Ronald Brus, Owner and Board Participant of myTomorrows, included: “ When we established myTomorrows in 2012, we imagined a far better means to attach individuals with encouraging treatments– one that enhances medication advancement and increases accessibility to advancement. This financial investment notes the start of a following stage of increased development and globally influence.“

Established In 2012, myTomorrows is a worldwide HealthTech firm that links individuals, medical professionals, test websites, and BioPharma companions to allow earlier and much better accessibility to pre-approval therapies.

With a centralised, multi-stakeholder system, myTomorrows incorporates AI-driven understandings with human know-how to provide customized services that intend to conquer a few of today’s best obstacles to client gain access to.

Headquartered in Amsterdam, with a workplace in New york city City, myTomorrows has actually sustained greater than 16,900 individuals and 2,800 medical professionals throughout 340+ websites in over 133 nations.

With greater than 300 million individuals globally encountering problems without accepted therapy choices, and over 10,000 treatments presently in advancement or waiting for authorization– myTomorrows is dealing with among health care’s most immediate difficulties: linking the void in between clinical improvement and client accessibility to pre-approval therapies, that include scientific tests and broadened gain access to programs (EAPs).

The brand-new financial investment will certainly increase myTomorrows’ worldwide development and more establish its AI-driven worldwide system that links medical professionals and their individuals, test websites and BioPharma companions to enhance gain access to and understanding.

It will certainly likewise enhance cooperations with market companions to reduce scientific advancement timelines and boost real-world information capacities, sustaining proof generation and regulative understanding.

“ Avego is pleased to sustain myTomorrows in its goal to change exactly how individuals and medical professionals gain access to treatments in advancement,” stated James Flexner, Taking Care Of Companion at Avego. “ Our company believe myTomorrows is distinctly placed to get rid of obstacles for individuals and service providers while working as a necessary companion to BioPharma“

For BioPharma companions, myTomorrows gives scientific test employment, broadened gain access to services, and real-world information collection. For test websites, the system supplies a unified recommendation administration system that boosts test exposure and allows real-time standing updates.

EU-Startups has actually included myTomorrows several times– initially in 2017, reporting on its €10 million funding round, and later on in its 2021 summary of top healthcare startups in the Netherlands.

The message As millions await approved therapies, myTomorrows strengthens its global patient-access mission with €25 million showed up initially on EU-Startups.